24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
BiondVax
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
10:00
ToBe Influence Innovation automates the fight against the mite killing honeybee colonies
09:54
AI’s biggest labs confront a problem of their own making
09:00
Tevel's flying robots pick fruit that's too high or too risky for people
13:43
Nobody installed the software that now runs your office
More stories
Buzz
Most popular
Daily
Weekly
1
Intel CEO says CPU demand is so strong the company can serve only 50% of customers
2
Israel’s sixth submarine is coming home after a highly secretive journey
3
Netanyahu calls off Elon Musk meeting as U.S. trip is sharply shortened
4
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
5
What Nebius really bought when it bought Tavily
More news
BiondVax
2 stories about BiondVax
Flu Season Might Soon Pass, for Good
11.12.19
|
Lilach Baumer
The researchers behind Jerusalem-based BiondVax talked to Calcalist, discussing their potential universal flu vaccine, currently undergoing a phase 3 clinical trial
Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax
17.07.19
|
Micky Grunfeld
Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials
